More on treating chronic insomnia

In “Treating chronic insomnia: An alternating medication strategy” (CURRENT PSYCHIATRY, October 2023, p. 25-31, doi:10.12788/cp.0397), Dr. Kaplan correctly identified tolerance and tachyphylaxis as significant problems when prescribing traditional hypnotics, and proposed a solution of using 2 sleep medications, each having a different mechanism of action, on an alternating schedule. However, with the availability of the dual orexin receptor antagonists (DORAs) darpdone, lemborexant, and suvorexant, this approach is unnecessary. Moreover, the mechanism of action of orexin receptor antagonism directly addresses extant hyperarousal by decreasing wake signaling, without any deleterious effect on sleep architecture. Additionally, the DORAs are not associated with physiological dependence, withdrawal, or rebound. Their efficacy profile is as good as or better than other FDA-approved agents for insomnia disorder. An obstacle to their use is that they are not yet available as generic products, but access is facilitated by the manufacturers’ patient assistance programs. Additional resources elaborate on indirect comparisons among agents using number needed to treat and number needed to harm, metrics that are helpful when clinically appraising new agents.2,5

Leslie Citrome, MD, MPH
Valhalla, New York

References

Disclosures
Dr. Citrome is a consultant for AbbVie/Allergan, Acadia, Adams, Alkermes, Angelini, Astellas, Avanir, Axsome, BioXcel, Boehringer Ingelheim, Cadent Therapeutics, Cerevel, Clinilabs, COMPASS, Eisai, Enteris Biopharma, HLS Therapeutics, Idorsia, Impel, Immune Bio, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Lyndra, Medavante-ProPhase, Marvin, Merck, Mitsubishi Tanabe Pharma, Neurilis, Neurocrine, Novartis, Noven, Otsuka, Ovid, Praxis, Recordati, Relmada, Reviva, Sage, Sunovion, Supernus, Teva, the University of Arizona, and Vanda, and has done one-off ad hoc consulting for individuals/entities conducting marketing, commercial, or scientific scoping research. He is a speaker for AbbVie/Allergan, Acadia, Alkermes, Angelini, Axsome, BioXcel, Eisai, Idorsia, Intra-Cellular Therapies, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Recordati, Sage, Sunovion, Takeda, Teva, and CME activities organized by medical education companies such as Medscape, NACCME, NEI, Vindico, universities, and professional organizations/societies.
doi: 10.12788/cp.0421

ANNOUNCEMENT FROM THE PUBLISHER

Dear Current Psychiatry Reader:

Frontline Medical Communications Inc has made the difficult decision to discontinue publication of CURRENT PSYCHIATRY, effective with this issue. We thank CURRENT PSYCHIATRY’s esteemed Editorial Board, loyal readers, and dedicated authors for their support. It has been our privilege to publish CURRENT PSYCHIATRY for over 20 years.

The online archive of clinical content for CURRENT PSYCHIATRY (2002-2023) remains accessible on MDedge Psychiatry (https://www.mdedge.com/psychiatry/archived-issues/currentpsychiatry). Reprint requests can be directed to Wright’s Media via email frontline@wrightsmmedia.com or telephone (877-652-5295).

For the latest news and information on psychiatry, continue to turn to MDedge Psychiatry at https://www.mdedge.com/psychiatry.